Annals of Oncology 10:317-321, 1999
© 1999 European Society for Medical Oncology
research-article |
Incidence of second neoplasms in patients with MALT lymphoma: No increase in risk above the background population
1Divisions of Medical Oncology Vancouver, Canada
2Divisions of Cancer Control Research Vancouver, Canada
3Divisions of Pathology, British Columbia Cancer Agency and the University of British Columbia Vancouver, Canada
J. M. Connors, MD, Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Avenue, V5Z 4E6, Canada E-mail: jconnors{at}bccancer.bc.ca
Background: Lymphomas of mucosa associated lymphoid tissue (MALT) are a special type of extranodal lymphoma, possibly related to chronic antigenic stimulation. Increased cancer susceptibility may also contribute to the development of MALT lymphoma (MALToma). It has been suggested that patients with MALToma have an increased incidence of other malignancies.
Patients and methods: We retrospectively reviewed the histology and clinical records of 147 patients with MALToma, including 51 cases of gastric MALToma. The incidence of any second malignancy was confirmed with a provincial registry. The relative rates of cancer, excluding MALToma, were calculated relative to the background population of the same age group and secular year.
Results: A total of 41 tumors occurred in 32 patients (21%), including 22 solid tumors. The incidence of solid tumors in the gastric MALToma group was 15%. Seven patients had two or more second malignancies. Cancer occurred before diagnosis of MALToma in 29 cases, concurrent with MALToma in three, and after MALToma in nine. Follow-up of the surviving patients is short (median 17.6 months). The relative rate from birth of a second malignancy was 0.86 in the whole group (90% confidence interval (CI): 0.62–1.16) and 0.95 (90% CI: 0.55–1.54) in the gastric MALToma group. The rates were roughly the same if skin cancers were excluded.
Conclusions: The incidence of second cancers in this series is similar to previous reports. However, when compared to an age-matched population followed for the same period of time, MALToma patients do not appear to have a statistically significant increased rate of cancers.
lymphoma, MALT, second neoplasm
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Arcaini, S. Burcheri, A. Rossi, C. Pascutto, F. Passamonti, E. Brusamolino, M. Paulli, E. Orlandi, M. Buelli, P. Viero, et al. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy Clin. Cancer Res., January 1, 2007; 13(1): 182 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Tsang, M. K. Gospodarowicz, M. Pintilie, W. Wells, D. C. Hodgson, A. Sun, M. Crump, and B. J. Patterson Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome J. Clin. Oncol., November 15, 2003; 21(22): 4157 - 4164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cavalli, P. G. Isaacson, R. D. Gascoyne, and E. Zucca MALT Lymphomas Hematology, January 1, 2001; 2001(1): 241 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zucca, F. Bertoni, E. Roggero, and F. Cavalli The gastric marginal zone B-cell lymphoma of MALT type Blood, July 15, 2000; 96(2): 410 - 419. [Full Text] [PDF]
|
|